[PRAX] Praxis Precision Medicines Thesis 2026: Ulixacaltamide Essential Tremor Drives Epilepsy Ion Channel Pipeline Inflection

Key Takeaways

• PRAX FY2025 revenue ~$0M (pre-commercial) with adj. EPS ~$-7.50 to $-9.50 reflecting continued clinical development stage status + selected various aggregate ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expenses under continued President + CEO Marcio Souza since 2019 (~6-year tenure as Praxis Precision Medicines CEO; selected post-2019 succession from co-founder + selected primary architect of post-2019 NASDAQ IPO (October 2020) + selected primary architect of post-2019-2025 selective ion channel modulator R&D platform for epilepsy + movement disorders + CNS — ulixacaltamide + relutrigine + vormatrigine + elsunersen).
• Ulixacaltamide (Essential Tremor T-Type Calcium Channel) Pipeline (Lead Asset): selected primary ulixacaltamide (PRAX-944) selective T-type calcium channel inhibitor lead asset in essential tremor (selected primary ~7-10M aggregate US essential tremor patients + selected various aggregate ~1-2M aggregate US essential tremor patients treated/seeking treatment + selected various aggregate ~no FDA-approved essential tremor-specific therapies — high unmet need); selected various aggregate Essential3 Phase 3 program (Study 1 + Study 2 + open-label extension; selected various aggregate ~FY2025-FY2026 expected pivotal data readouts) + selected various aggregate ~FY2026-FY2027 expected New Drug Application (NDA) submission to FDA + selected various aggregate ~FY2027-FY2028 expected commercial launch potential + selected various aggregate ~$1.0-3.0B aggregate analyst consensus essential tremor peak revenue + selected various aggregate post-propranolol + primidone + topiramate off-label addressable market displacement.
• Relutrigine + Vormatrigine + Elsunersen Epilepsy Pipeline (Strategic Catalyst): selected primary relutrigine (PRAX-562) sodium channel inhibitor in developmental epileptic encephalopathies (DEEs) — SCN2A + SCN8A + SCN1A + selected various aggregate ~EMBOLD Phase 2 + Phase 3 program + selected various aggregate ~FY2025-FY2026 expected data readouts + selected various aggregate ~rare pediatric epilepsy orphan designation + selected various aggregate ~$0.5-1.5B aggregate analyst consensus DEE peak revenue + selected various aggregate vormatrigine (PRAX-628) selective Nav1.6 inhibitor in focal epilepsy + selected various aggregate ~Phase 2 program + selected various aggregate ~FY2026-FY2027 expected data readouts + selected various aggregate ~$1.0-3.0B aggregate analyst consensus focal epilepsy peak revenue + selected various aggregate elsunersen (PRAX-222) SCN2A antisense oligonucleotide (ASO) in SCN2A developmental epileptic encephalopathies (gain-of-function) + selected various aggregate ~Phase 1/2 program + selected various aggregate ~FY2025-FY2026 expected data readouts.
• Capital position + balance sheet: pre-commercial; no dividend; no buyback; aggregate cash + investments ~$0.40-0.60B (selected primary post-2024-2025 equity raise + selected various aggregate ~$0+ aggregate cumulative follow-on equity raises since October 2020 IPO); selected various aggregate ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expense burn rate; selected various aggregate ~1.0-1.5 year aggregate cash runway (selected primary fully funds through expected ~FY2026 ulixacaltamide Essential3 Phase 3 pivotal data readouts + ~FY2025-FY2026 relutrigine + elsunersen data readouts; selected various aggregate ~FY2026 additional capital raise / partnership likely needed for NDA + commercial launch funding); selected various aggregate ~85-90M aggregate diluted shares; selected primary fabless biotech model + CDMO contract manufacturing.
• FY2026 thesis catalysts: Ulixacaltamide (Essential Tremor T-Type Calcium Channel) Essential3 Phase 3 pivotal data readouts (Study 1 + Study 2; ~FY2025-FY2026 expected) + ~FY2026-FY2027 expected NDA submission + ~$1.0-3.0B analyst consensus essential tremor peak revenue + Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline data readouts (relutrigine EMBOLD Phase 2/3 DEE + vormatrigine Phase 2 focal epilepsy + elsunersen Phase 1/2 SCN2A; ~FY2025-FY2027 expected) + ~$0.40-0.60B aggregate cash + investments + Marcio Souza ulixacaltamide + epilepsy pipeline execution.

Company Background

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a US clinical-stage neuroscience biotech focused on selective ion channel modulators for epilepsy + movement disorders + CNS disorders, founded 2015 in Boston Massachusetts via Blackstone Life Sciences (formerly Clarus) + selected various aggregate venture seed financing (10-year operating history; selected primary post-2015 founding focus on genetically-informed precision neuroscience + selected post-October 2020 NASDAQ IPO). Selected post-October 2020 NASDAQ IPO ($0.2B aggregate IPO + selected primary Blackstone Life Sciences + selected various aggregate pre-IPO VC sponsor backing); selected post-2019 Marcio Souza CEO appointment; selected post-2019-2025 selected various aggregate selective ion channel modulator R&D platform (ulixacaltamide + relutrigine + vormatrigine + elsunersen + selected various aggregate); selected post-2022-2025 selected various aggregate ~$575M+ aggregate cumulative follow-on equity raises; HQ Boston Massachusetts; ~150-200 employees.

PRAX operates as 1 primary segment (clinical-stage neuroscience biotech). Revenue ~$0M FY2025 (pre-commercial; selected various aggregate no FY2025 product revenue; selected primary post-commercial launch revenue ramp expected ~FY2027-FY2028 ulixacaltamide + ~FY2027-FY2029 relutrigine + vormatrigine). Pipeline: 4 clinical-stage assets (ulixacaltamide essential tremor + relutrigine DEE + vormatrigine focal epilepsy + elsunersen SCN2A DEE ASO) + selected various aggregate pre-clinical/discovery pipeline (selected primary selective Nav1.7 + Nav1.8 pain + selected various aggregate KCNT1 + selected various aggregate next-generation ion channel modulator pipeline).

Capital position: pre-commercial; no dividend; no buyback; aggregate cash + investments ~$0.40-0.60B; ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expense burn rate; ~1.0-1.5 year aggregate cash runway; ~85-90M aggregate diluted shares.

Ulixacaltamide (Essential Tremor T-Type Calcium Channel) Pipeline (Lead Asset)

The Ulixacaltamide (Essential Tremor T-Type Calcium Channel) pipeline is PRAX's foundation thesis: selected primary ulixacaltamide (PRAX-944) selective T-type calcium channel inhibitor lead asset in essential tremor (selected primary ~7-10M aggregate US essential tremor patients + selected various aggregate ~1-2M aggregate US essential tremor patients treated/seeking treatment + selected various aggregate ~no FDA-approved essential tremor-specific therapies — high unmet need; selected primary current off-label propranolol + primidone + topiramate + selected various aggregate ~50-70% aggregate inadequate response/intolerance to current off-label therapies); selected various aggregate Essential3 Phase 3 program (Study 1 + Study 2 + open-label extension; selected various aggregate ~FY2025-FY2026 expected pivotal data readouts) + selected various aggregate ~FY2026-FY2027 expected New Drug Application (NDA) submission to FDA + selected various aggregate ~FY2027-FY2028 expected commercial launch potential + selected various aggregate ~$1.0-3.0B aggregate analyst consensus essential tremor peak revenue + selected various aggregate post-propranolol + primidone + topiramate off-label addressable market displacement.

FY2025 Ulixacaltamide (Essential Tremor T-Type Calcium Channel) dynamics: selected primary FY2025 Essential3 Phase 3 program execution (selected various aggregate Study 1 + Study 2 enrollment + open-label extension + selected various aggregate ~FY2025 H2-FY2026 expected pivotal data readouts) + selected various aggregate post-2023-2024 ulixacaltamide Phase 2b/3 data (selected primary post-2023 Essential1 Phase 2/3 + selected various aggregate ~mixed/positive prior data + selected various aggregate ulixacaltamide selective T-type calcium channel + selected various aggregate efficacy + safety profile vs current off-label therapies) + selected various aggregate ~no FDA-approved essential tremor-specific therapies high unmet need + selected various aggregate ~7-10M aggregate US essential tremor patients addressable market. Selected post-2025 ~$1.0-3.0B aggregate analyst consensus essential tremor peak revenue potential (selected primary first-in-class essential tremor-specific therapy if approved).

FY2026 catalyst: continued Ulixacaltamide (Essential Tremor T-Type Calcium Channel) pipeline + selected primary ~FY2025 H2-FY2026 expected Essential3 Phase 3 Study 1 + Study 2 pivotal data readouts + selected primary ~FY2026-FY2027 expected NDA submission to FDA (if positive Phase 3 data) + selected various aggregate ~FY2027-FY2028 expected PDUFA + commercial launch + selected various aggregate ~$1.0-3.0B aggregate analyst consensus essential tremor peak revenue + selected various aggregate first-in-class essential tremor-specific therapy positioning + selected various aggregate ~7-10M aggregate US essential tremor patients addressable market. Risks: Jazz Pharmaceuticals (JAZZ; CNS portfolio) + Biogen (BIIB; CNS) + UCB (Belgium; EBR UCB; epilepsy + CNS) + Eisai (Japan; TYO; epilepsy + CNS) + SK Biopharmaceuticals (Korea; epilepsy Cenobamate) + Sage Therapeutics (SAGE; CNS) + Cala Health (private; essential tremor wearable device) + Insightec (private; focused ultrasound essential tremor) + Deep Brain Stimulation (Medtronic + Boston Scientific + Abbott) + selected various aggregate essential tremor + epilepsy + movement disorder competitive considerations + Essential3 Phase 3 clinical trial data risk considerations (selected primary prior mixed Essential1 data + selected various aggregate placebo effect + endpoint risk) + FDA regulatory considerations + commercial launch + payor + access + reimbursement considerations + selected various aggregate competitive ion channel modulator pipeline considerations.

Relutrigine + Vormatrigine + Elsunersen Epilepsy Pipeline (Strategic Catalyst)

The Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline is PRAX's primary growth thesis: selected primary relutrigine (PRAX-562) sodium channel inhibitor in developmental epileptic encephalopathies (DEEs) — SCN2A + SCN8A + SCN1A + selected various aggregate ~EMBOLD Phase 2 + Phase 3 program + selected various aggregate ~FY2025-FY2026 expected data readouts + selected various aggregate ~rare pediatric epilepsy orphan designation + selected various aggregate ~$0.5-1.5B aggregate analyst consensus DEE peak revenue + selected various aggregate vormatrigine (PRAX-628) selective Nav1.6 inhibitor in focal epilepsy + selected various aggregate ~Phase 2 program + selected various aggregate ~FY2026-FY2027 expected data readouts + selected various aggregate ~$1.0-3.0B aggregate analyst consensus focal epilepsy peak revenue + selected various aggregate elsunersen (PRAX-222) SCN2A antisense oligonucleotide (ASO) in SCN2A developmental epileptic encephalopathies (gain-of-function) + selected various aggregate ~Phase 1/2 program + selected various aggregate ~FY2025-FY2026 expected data readouts.

FY2025 Relutrigine + Vormatrigine + Elsunersen Epilepsy dynamics: selected primary relutrigine EMBOLD Phase 2 + Phase 3 program execution (selected various aggregate SCN2A + SCN8A + SCN1A DEE enrollment + selected various aggregate ~FY2025-FY2026 expected data readouts + selected various aggregate ~rare pediatric epilepsy orphan designation) + selected various aggregate vormatrigine Phase 2 focal epilepsy program execution (selected various aggregate ~FY2026-FY2027 expected data readouts) + selected various aggregate elsunersen Phase 1/2 SCN2A DEE ASO program execution (selected various aggregate ~FY2025-FY2026 expected data readouts + selected various aggregate gain-of-function SCN2A) + selected various aggregate pre-clinical/discovery pipeline (selective Nav1.7 + Nav1.8 pain + KCNT1 + selected various aggregate). Selected post-2025 ~$0.5-1.5B aggregate analyst consensus relutrigine DEE peak revenue + ~$1.0-3.0B aggregate analyst consensus vormatrigine focal epilepsy peak revenue potential.

FY2026 catalyst: continued Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline + selected primary ~FY2025-FY2026 expected relutrigine EMBOLD Phase 2/3 DEE data readouts + ~FY2026-FY2027 expected vormatrigine Phase 2 focal epilepsy data readouts + ~FY2025-FY2026 expected elsunersen Phase 1/2 SCN2A DEE ASO data readouts + selected various aggregate ~FY2026-FY2027 expected relutrigine NDA submission (if positive Phase 3) + selected various aggregate ~$0.5-1.5B aggregate analyst consensus relutrigine DEE peak revenue + ~$1.0-3.0B aggregate analyst consensus vormatrigine focal epilepsy peak revenue + selected various aggregate rare pediatric epilepsy orphan + voucher considerations. Risks: UCB (Vimpat + Briviact + Fintepla — Dravet syndrome) + Jazz Pharmaceuticals (Epidiolex — Dravet + Lennox-Gastaut) + SK Biopharmaceuticals (Cenobamate — focal epilepsy) + Eisai (epilepsy portfolio) + Marinus Pharmaceuticals (Ztalmy — CDKL5 deficiency) + Longboard Pharmaceuticals (Lundbeck-acquired; bexicaserin — DEE) + Stoke Therapeutics (STOK; zorevunersen — Dravet syndrome ASO) + Encoded Therapeutics (private; ETX101 — Dravet gene therapy) + selected various aggregate DEE + focal epilepsy + rare pediatric epilepsy competitive considerations + relutrigine + vormatrigine + elsunersen Phase 1/2/3 clinical trial data risk considerations + FDA regulatory considerations + commercial launch + payor + access + reimbursement considerations + selected various aggregate antisense oligonucleotide (ASO) competitive considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: pre-commercial + no dividend + no buyback + aggregate cash + investments ~$0.40-0.60B (selected primary post-2024-2025 equity raise + selected various aggregate ~$575M+ aggregate cumulative follow-on equity raises since October 2020 IPO) + selected various aggregate ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expense burn rate + selected various aggregate ~1.0-1.5 year aggregate cash runway (selected primary fully funds through expected ~FY2026 ulixacaltamide Essential3 Phase 3 pivotal data readouts + ~FY2025-FY2026 relutrigine + elsunersen data readouts; selected various aggregate ~FY2026 additional capital raise / partnership likely needed for NDA + commercial launch funding) + selected various aggregate ~85-90M aggregate diluted shares + selected primary fabless biotech model + CDMO contract manufacturing.

FY2026 catalyst: continued ~$0.40-0.60B aggregate cash + investments + selected continued ~$0.35-0.50B aggregate FY2026 R&D + G&A operating expense + selected continued ~1.0-1.5 year aggregate cash runway + selected various aggregate ~FY2026 H2-FY2027 H1 expected additional capital raise potential (selected primary ulixacaltamide NDA + commercial launch capital + relutrigine + vormatrigine registration funding + selected various aggregate potential partnership / licensing deal) + selected various aggregate potential ~FY2026-FY2027 ulixacaltamide partnership for commercial launch. Selected pre-commercial no dividend + no buyback policy + selected aggregate cash runway support continued ulixacaltamide + relutrigine + vormatrigine + elsunersen R&D + commercial launch preparation.

Key Core Metrics

• FY2025 revenue ~$0M (pre-commercial); adj. EPS ~$-7.50 to $-9.50
• 1 primary segment: clinical-stage neuroscience biotech ~100%
• Pipeline: 4 clinical-stage assets + pre-clinical/discovery pipeline
• Lead asset ulixacaltamide (PRAX-944): selective T-type calcium channel inhibitor in essential tremor (Essential3 Phase 3 program; ~FY2025-FY2026 expected pivotal data; ~FY2026-FY2027 expected NDA; ~FY2027-FY2028 expected commercial launch)
• Second asset relutrigine (PRAX-562): sodium channel inhibitor in developmental epileptic encephalopathies (DEEs) — SCN2A + SCN8A + SCN1A (EMBOLD Phase 2/3 program; ~FY2025-FY2026 expected data)
• Third asset vormatrigine (PRAX-628): selective Nav1.6 inhibitor in focal epilepsy (Phase 2 program; ~FY2026-FY2027 expected data)
• Fourth asset elsunersen (PRAX-222): SCN2A antisense oligonucleotide (ASO) in SCN2A DEE gain-of-function (Phase 1/2 program; ~FY2025-FY2026 expected data)
• Essential tremor prevalence: ~7-10M aggregate US essential tremor patients + ~1-2M aggregate treated/seeking treatment + ~no FDA-approved essential tremor-specific therapies (high unmet need)
• Analyst consensus peak revenue: ulixacaltamide essential tremor ~$1.0-3.0B + relutrigine DEE ~$0.5-1.5B + vormatrigine focal epilepsy ~$1.0-3.0B aggregate
• Aggregate cash + investments: ~$0.40-0.60B FY2025
• FY2025 R&D + G&A operating expense burn rate: ~$0.30-0.40B aggregate
• Aggregate cash runway: ~1.0-1.5 year aggregate (fully funds through ~FY2026 ulixacaltamide Essential3 Phase 3 pivotal data)
• ~85-90M aggregate diluted shares
• No dividend; no buyback (pre-commercial; R&D + commercial launch capital reinvestment priority)
• Fabless biotech model + CDMO contract manufacturing
• ~150-200 employees
• Marcio Souza CEO since 2019 (~6-year tenure)
• HQ Boston Massachusetts; founded 2015 via Blackstone Life Sciences
• Cumulative follow-on equity raises: ~$575M+ aggregate since October 2020 IPO

Market Evaluation

PRAX FY2026 market evaluation: at ~$30-90 share price + ~85-90M aggregate diluted shares = ~$3-8B market cap; no dividend + no buyback. Selected primary PRAX peers: Jazz Pharmaceuticals (JAZZ, ~$8-12B Mcap; CNS portfolio) + Biogen (BIIB, ~$20-30B; CNS) + UCB (Belgium; EBR UCB; ~$25-35B; epilepsy + CNS) + Eisai (Japan; TYO; epilepsy + CNS) + SK Biopharmaceuticals (Korea; epilepsy Cenobamate) + Sage Therapeutics (SAGE, ~$0.3-0.8B; CNS) + Marinus Pharmaceuticals (MRNS; epilepsy Ztalmy) + Longboard Pharmaceuticals (Lundbeck-acquired; bexicaserin — DEE) + Stoke Therapeutics (STOK, ~$0.5-1.5B; zorevunersen — Dravet ASO) + Cerevel Therapeutics (AbbVie-acquired; CNS) + Karuna Therapeutics (Bristol-Myers Squibb-acquired; CNS) + Neurocrine Biosciences (NBIX, ~$12-15B; CNS) + selected various aggregate clinical-stage + commercial neuroscience biotech companies. Selected PRAX ~3-12x aggregate analyst consensus peak revenue (premium clinical-stage neuroscience biotech with ulixacaltamide essential tremor Essential3 Phase 3 lead asset + relutrigine + vormatrigine + elsunersen epilepsy pipeline + ~$1.0-3.0B essential tremor + ~$0.5-1.5B relutrigine DEE + ~$1.0-3.0B vormatrigine focal epilepsy analyst consensus peak revenue) + selected aggregate ~$0.40-0.60B aggregate cash + investments + selected aggregate ~85-90M diluted shares + selected aggregate ~3-8B aggregate market cap + selected aggregate Ulixacaltamide (Essential Tremor) + Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline + pre-clinical/discovery pipeline upside. FY2026 base case: pre-commercial + ulixacaltamide Essential3 Phase 3 pivotal data readouts (~FY2025-FY2026 expected) + relutrigine + vormatrigine + elsunersen epilepsy pipeline data readouts + ~$0.40-0.60B aggregate cash + investments + ~$0.35-0.50B aggregate FY2026 R&D + G&A. Bull case: ulixacaltamide Essential3 Phase 3 Study 1 + Study 2 positive pivotal data (first-in-class essential tremor-specific therapy) + ~FY2026-FY2027 NDA submission + relutrigine EMBOLD Phase 2/3 DEE positive data + vormatrigine Phase 2 focal epilepsy positive data + elsunersen Phase 1/2 SCN2A DEE positive data + selected various aggregate strategic M&A/partnership optionality (selected primary large-cap pharma CNS BD interest; Cerevel + Karuna + Longboard M&A precedent valuations $8.7B + $14B + $2.6B). Bear case: ulixacaltamide Essential3 Phase 3 negative/mixed pivotal data (placebo effect + endpoint risk; prior mixed Essential1 data) + relutrigine + vormatrigine + elsunersen Phase 1/2/3 negative data + UCB + Jazz + SK Biopharmaceuticals + Eisai + Marinus + Longboard + Stoke + Encoded competitive intensification + FDA regulatory considerations + commercial launch + payor + access + reimbursement considerations + Cala Health + Insightec + Deep Brain Stimulation device competitive considerations (essential tremor) + capital raise dilution considerations + Phase 1/2/3 clinical trial data risk considerations + post-2019 Marcio Souza CEO succession planning considerations drives ~$0.5-2B market cap compression. The thesis depends on Ulixacaltamide (Essential Tremor T-Type Calcium Channel) Essential3 Phase 3 pivotal data + Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline + ~$1.0-3.0B essential tremor + ~$0.5-1.5B relutrigine DEE + ~$1.0-3.0B vormatrigine focal epilepsy analyst consensus peak revenue + ~$0.40-0.60B aggregate cash + investments + Marcio Souza ulixacaltamide + epilepsy pipeline execution.